Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Inclusion Criteria:

* Patients with histologically proven newly diagnosed stage IV or stage IIIB non-squamous Non-small Cell Lung Cancer (NSCLC) - Recurrent advanced NSCLC will be allowed if they have never received chemotherapy for metastatic disease. - Prior adjuvant chemotherapy will be allowed, if recurrence occurred ≥ 6 months after last treatment
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
* Washout period of 4 weeks for chemo/radiation/experimental agents
* Resolution of all toxicities to \< grade 2 prior to starting treatment (excluding alopecia)
* Patients must have \< Grade 2 pre-existing peripheral neuropathy (per CTCAE)
* Adequate hepatic, renal, and bone marrow functions
* Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
* Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential

Exclusion Criteria:

* Patient with New York Heart Association class III or IV heart failure
* Women of child bearing potential (WOCBP) are not currently pregnant or breast-feeding
* Co-existing malignancy or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma
* Previous anaphylactic or severe allergic reaction to paclitaxel and/or docetaxel will be excluded
* Grade ≥2 peripheral neuropathy at baseline assessment from any cause
* Symptomatic brain metastases will be excluded. Treated Brain metastases will be allowed that are neurologically stable.
* Patients with adenocarcinoma with activating EGFR mutation (exon 19 deletions / insertions, exon 21 point mutations) or EML4-ALK translocation are excluded unless they are ineligible for epidermal growth factor receptor (EGFR) or ALK targeting agents.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.